HDM1002
Phase 3Small molecule
HDM1002 is one of 141 small molecule programs targeting DM1. It is currently in Phase 3.
6
Indications
11
Total Trials
10
Active Trials
140
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
150 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1DWP16001
Daewoong Pharmaceutical Co. LTD.Phase 3
Maridebart Cafraglutide
AmgenPhase 3
Enavogliflozin
Daewoong Pharmaceutical Co. LTD.Phase 3
GZR18
GGan & Lee Pharmaceuticals.
Phase 3
HDM1002
HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
Elecoglipron
AstraZenecaPhase 3
Dorzagliatin
HHua Medicine Limited
Phase 3
Adenocard
AstellasPreclinical
NOVOLIN R
Novo NordiskPreclinical
Dostinex
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes Mellitus3 trials
Overweight3 trials
Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults
Not yet recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 3·NCT06885021·780 enrolled
Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
Not yet recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 2·NCT06500299·180 enrolled
HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects
Not yet recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1·NCT06520540·72 enrolled
DM12 trials
Empagliflozin1 trial
Atorvastatin1 trial
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
Not yet recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1·NCT06601517·30 enrolled
1 more indication
Interaction1 trial
A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy Subjects
Not yet recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1·NCT06562088·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HDM1002. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details